NEUROCRINE BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 143.2 USD | +1.04% |
|
+4.11% | +8.67% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 2.22B | Sales 2025 * | 2.54B | Capitalization | 14.41B |
|---|---|---|---|---|---|
| Net income 2024 * | 439M | Net income 2025 * | 666M | EV / Sales 2024 * | 5.59 x |
| Net cash position 2024 * | 2B | Net cash position 2025 * | 2.79B | EV / Sales 2025 * | 4.57 x |
| P/E ratio 2024 * |
34.4
x | P/E ratio 2025 * |
22.6
x | Employees | 1,448 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.73% |
More Fundamentals
* Assessed data
More news
Latest transcript on Neurocrine Biosciences, Inc.
More recommendations
More press releases
| 1 day | +1.04% | ||
| 1 week | +4.11% | ||
| Current month | +4.11% | ||
| 1 month | +3.07% | ||
| 3 months | +5.06% | ||
| 6 months | +22.72% | ||
| Current year | +8.67% |
1 week
139.23
144.09
1 month
130.13145.22
Current year
128.00148.37
1 year
89.04148.37
3 years
71.88148.37
5 years
71.88148.37
10 years
12.63148.37
| Managers | Title | Age | Since |
|---|---|---|---|
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
| Director of Finance/CFO | 44 | 17-10-31 | |
Jude Onyia
CTO | Chief Tech/Sci/R&D Officer | 60 | 21-11-29 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 99-03-31 |
George Morrow
BRD | Director/Board Member | 72 | 15-09-30 |
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 13.65% | 0 M€ | +10.86% | - | |
| 3.81% | 0 M€ | -3.50% | - | |
| 1.85% | 0 M€ | -.--% | ||
| 1.08% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-07 | 143.2 | +1.04% | 667,258 |
| 24-05-06 | 141.7 | +0.71% | 495,129 |
| 24-05-03 | 140.7 | +0.63% | 616,567 |
| 24-05-02 | 139.8 | -2.24% | 882,407 |
| 24-05-01 | 143 | +3.99% | 1,601,920 |
Delayed Quote Nasdaq, May 07, 2024 at 04:00 pm EDT
More quotes
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering and developing pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinsonâs disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 milligrams (mg), 60 mg and 80 mg capsules); ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinsonâs disease; ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women. Its pipeline also includes DYSVAL (valbenazine), ORIAHNN (elagolix, estradiol, and norethindrone acetate and elagolix capsules), ALKINDI/ALKINDI SPRINKLE (hydrocortisone), and EFMODY (hydrocortisone modified-release hard capsules).
Calendar
2024-05-22
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
143.2
USD
Average target price
157.8
USD
Spread / Average Target
+10.21%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.67% | 14.41B | |
| +10.44% | 107B | |
| +0.82% | 106B | |
| +7.69% | 23.47B | |
| -13.89% | 21.9B | |
| -6.64% | 18.77B | |
| -37.26% | 17.85B | |
| -10.98% | 16.78B | |
| +41.08% | 12.86B | |
| +327.78% | 8.78B |
- Stock Market
- Equities
- NBIX Stock